Novel cytotoxic agents: epothilones (Q28279384)

American Journal of Health-System Pharmacy

Europe PubMed Central

title

Novel cytotoxic agents: epothilones (English)

0 references

0 references

Susan Goodin

1

0 references

language of work or name

English

0 references

publication date

15 May 2008

0 references

published in

0 references

volume

65

0 references

issue

10 Suppl 3

0 references

page(s)

S10-5

0 references

cites work

Extending survival with chemotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Novel formulations of taxanes: a review. Old wine in a new bottle?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

31 March 2020

Microtubule functions

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Efficacy and safety of ixabepilone, a novel epothilone analogue.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080089